Ariad Pharmaceuticals Inc (ARIA): Paris Panayiotopoulos , CEO of Ariad Pharmaceuticals Inc purchased 26,990 shares on May 12, 2016. The Insider buying transaction was reported by the company on May 13, 2016 to the Securities and Exchange Commission. The shares were purchased at $7.41 per share for a total value of $199,995.91 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 2, 2016, Timothy P Clackson (President, R&D, CSO) sold 11,700 shares at $7.14 per share price.On Mar 22, 2016, Edward M Fitzgerald (Executive VP) sold 5,417 shares at $6.47 per share price.Also, On Mar 22, 2016, David L Berstein (SVP, Chief IP Counsel) sold 2,375 shares at $6.47 per share price.On Mar 22, 2016, Martin J Duvall (EVP, CCO) sold 4,000 shares at $6.47 per share price.
Ariad Pharmaceuticals: On Tuesday, May 10, 2016 heightened volatility was witnessed in Ariad Pharmaceuticals which led to swings in the share price. The shares opened for trading at $7.34 and hit $7.94 on the upside , eventually ending the session at $7.64, with a gain of 6.41% or 0.46 points. The heightened volatility saw the trading volume jump to 1,08,66,885 shares. The 52-week high of the share price is $10.07 and the company has a market cap of $1,459 M . The 52-week low of the share price is at $4.37.
Company has been under the radar of several Street Analysts.Ariad Pharmaceuticals is Reiterated by Barclays to Underweight and the brokerage firm has raised the Price Target to $ 8 from a previous price target of $6 .The Rating was issued on May 11, 2016.
ARIAD Pharmaceuticals Inc. is a global oncology company. The Company is engaged in the discovery development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib) brigatinib (AP26113) AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI) which is approved in the United States Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788 is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).